BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32457279)

  • 1. Entecavir Reduced Serum Hepatitis B Core-Related Antigen in Chronic Hepatitis B Patients with Hepatocellular Carcinoma.
    Mak LY; Ko KL; To WP; Wong DK; Seto WK; Fung J; Yuen MF
    Gut Liver; 2020 Sep; 14(5):665-668. PubMed ID: 32457279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    Hepatol Commun; 2022 Jan; 6(1):36-49. PubMed ID: 34532993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.
    Mak LY; Ko M; To E; Wong DK; Ma JH; Hui TL; Seto WK; Fung J; Lai CL; Yuen MF
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1817-1823. PubMed ID: 30786068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-treatment monitoring of liver fibrosis with serum hepatitis B core-related antigen in chronic hepatitis B.
    Chang XJ; Sun C; Chen Y; Li XD; Yu ZJ; Dong Z; Bai WL; Wang XD; Li ZQ; Chen D; Du WJ; Liao H; Jiang QY; Sun LJ; Li YY; Zhang CH; Xu DP; Chen YP; Li Q; Yang YP
    World J Gastroenterol; 2019 Aug; 25(32):4764-4778. PubMed ID: 31528100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
    Wu JW; Kao JH; Tseng TC
    Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
    Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
    To WP; Mak LY; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    J Viral Hepat; 2019 Dec; 26(12):1473-1480. PubMed ID: 31418973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
    Afifi AM; Elgenidy A; Hashim M; Awad AK; Jalal PK
    Rev Med Virol; 2022 Nov; 32(6):e2353. PubMed ID: 35441759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk population of progressive hepatic fibrosis in chronic hepatitis B patients on antiviral therapy.
    Chang X; Li Y; Sun C; Li X; Du W; Shang Q; Song L; Long Q; Li Q; Liu H; Wang J; Yu Z; Li J; Xiao G; Li L; Chen L; Tan L; Chen Y; Yang Y
    J Gastroenterol; 2023 May; 58(5):481-493. PubMed ID: 36928343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B.
    Kim BG; Park NH; Lee SB; Jeon S; Park JH; Jung SW; Jeong ID; Bang SJ; Shin JW
    Liver Int; 2018 Dec; 38(12):2269-2276. PubMed ID: 30052303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting.
    Idilman R; Gunsar F; Koruk M; Keskin O; Meral CE; Gulsen M; Elhan AH; Akarca US; Yurdaydin C
    J Viral Hepat; 2015 May; 22(5):504-10. PubMed ID: 25431108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation.
    Hu Z; Zeng H; Hou J; Wang J; Xu L; Zhang Y; Chen M; Zhou Z
    Viruses; 2022 Mar; 14(4):. PubMed ID: 35458386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients.
    Mak LY; Wong DK; Cheung KS; Seto WK; Fung J; Yuen MF
    BMC Gastroenterol; 2021 Mar; 21(1):123. PubMed ID: 33731023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation.
    Nishikawa H; Nishijima N; Enomoto H; Sakamoto A; Nasu A; Komekado H; Nishimura T; Kita R; Kimura T; Iijima H; Nishiguchi S; Osaki Y
    Medicine (Baltimore); 2016 Sep; 95(36):e4832. PubMed ID: 27603400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
    Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
    J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Yakushijin T; Iio S; Doi Y; Yamada A; Kaneko A; Hagiwara H; Mita E; Oshita M; Itoh T; Fukui H; Hijioka T; Katayama K; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hamasaki T; Hayashi N; Takehara T;
    J Gastroenterol; 2015 Jul; 50(7):785-94. PubMed ID: 25384794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
    Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
    Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
    Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
    Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.